Jun 2, 2006 (CIDRAP News) – An experimental DNA-based flu vaccine that is propelled into the skin on tiny particles instead of injected showed promise in a phase 1 trial involving 36 adults, according to a report published in the May 22 issue of Vaccine.All volunteers who received a 4-microgram (mcg) dose of the vaccine had a sufficient immune response at 21 days, according to the study. The DNA vaccine, developed by the biotech firm PowderMed of Oxford, UK, contains the hemagglutinin gene from a 1999 Panama strain of influenza A(H3N2).”This study is the first successful demonstration of immunogenicity of an influenza DNA vaccine in humans,” said senior author Hansi J. Dean, PhD, of the University of Wisconsin School of Medicine and Public Health in a May 31 PowderMed press release.Researchers divided the study participants (aged 19 to 50; mean, 31) into three groups of 12, with each group receiving one dose of either 1, 2, or 4 mcg of the vaccine. Vaccines were administered using a PowderJect XR-1 device, which employs pressurized helium to propel gold particles coated with plasmid DNA into the epidermis, according to the PowderMed Web site.At 21 days, only the 4-mcg group met one of the criteria for immune response used for vaccine licensure by the Committee for Proprietary Medical Products (CPMP) in the European Union. By day 56, the 4-mcg group met all three immune-response criteria, even though only one criterion is required to meet CPMP standards.By day 56, 64% (7/11) of patients in the 4-mcg group seroconverted, and 100% (11/11) achieved seroprotection, defined as an antibody titer of 40 or greater.Neither of the lower-dose groups met CPMP standards for antibody response by day 21, but both groups had by day 56. The 2-mcg group met all three criteria by day 56, while the 1-mcg group met one criterion.In addition, no volunteer reported serious side effects. Twenty-seven of the 36 participants reported mild to moderate local adverse events, and 23 reported mild to moderate systemic adverse events.The study authors concluded, “While the results of this study are promising, further development will be required for a commercially feasible DNA vaccine for influenza.””DNA vaccines have the potential to significantly limit the burden of disease,” said PowerMed CEO Clive Dix, PhD, in the press release. “The advantage of a DNA-based approach is that the vaccines can be manufactured very rapidly and in large quantities, while yielding an efficacious immune response at low doses.”In addition, according to a Reuters story published yesterday, the vaccine is stable and does not need to be refrigerated, or even administered by a healthcare professional.PowerMed will begin phase 2 trials later this year using both avian flu and annual flu strains, according to the Reuters article. A marketable vaccine is years away, according to Reuters.Drape RJ, Macklin MD, Barr LJ, et al. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 2006;24(21):4475-4481 [Abstract]
Football fans will get the chance to see the First Capital Plus Premier League trophy up close when it arrives in the country, Monday morning.With nine matches to go in the 2013-14 season, headline sponsor of the league, First Capital Plus Bank, a wholly-owned Ghanaian bank will present the new trophy to the league organisers.The trophy will be paraded through the streets of Accra from 11:00am from the Kotoka International Airport.Fans can catch a glimpse of the trophy before it reaches the Ghana Football Association headquarters at 2:00pm where it will be presented to the governing body.In attendance will be the President, Kwesi Nyantakyi, Executive Commitee members and representatives of the 16 Premier League sides.
Jurgen Klopp has been appointed Liverpool’s new manager on a three-year deal.The 48-year-old German replaces Brendan Rodgers, who was sacked on Sunday after three and a half years in charge with the club 10th in the Premier League.Klopp has been out of work since May, when he ended a seven-year spell at Borussia Dortmund to take a sabbatical.He is expected to have Zeljko Buvac and Peter Krawietz – his former assistants at the Bundesliga club – at Anfield.Sean O’Driscoll, who was Rodgers’ assistant, has left the club, while Gary McAllister has been moved from first-team coach to a new “ambassadorial position”.Klopp will be officially unveiled by Liverpool on Friday at 09:00 GMT –Follow Joy Sports on Twitter: @Joy997FM. Our hashtag is #JoySports
MASON CITY — A plea change hearing has been scheduled for a Mason City man accused of shooting at an occupied car in November in southeastern Mason City.Police were called on November 24th to the area of 8th and South Kentucky, where after investigating arrested 18-year-old Manuel Zamorano of Mason City.Zamorano was accused of firing four shots at either a car or at a person nearby. Nobody was struck by any of the bullets, which also did not hit the car. Zamorano while being arrested allegedly also spit on a police officer and an Iowa State Patrol trooper also received a cut to their hand.Zamorano was charged with terrorism, two different counts of assault on a police officer, interference with official acts and possession of marijuana.Zamorano was scheduled to be tried on the charges starting on March 26th, but online court records show a plea change hearing has been scheduled for April 1st in Cerro Gordo County District Court.